NERV
Minerva Neurosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.43
−5.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 5.3B | 5.8M | 11.9M | 12.7M | 14.6M |
| SG&A Expense | 11.4B | 9.3M | 9.9M | 10.4M | 10.6M |
| General & Admin Expense | 11.4B | 9.3M | 9.9M | 10.4M | 10.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (16.7B) | — | — | — | — |
| Total Operating Expenses | 35.1M | 15.1M | 21.8M | 23.1M | 25.2M |
| Cost and Expenses | 35.1M | 15.1M | 21.8M | 23.1M | 25.2M |
| Operating Income (EBIT) | (35.1M) | (15.1M) | (21.8M) | (23.1M) | (25.2M) |
| Non-Operating | |||||
| Interest Income | 1.9M | 948.1K | 1.3M | 1.4M | 556.9K |
| Interest Expense | — | — | 4.6M | 8.3M | 7.4M |
| Net Interest Income | 1.9M | 948.1K | (3.3M) | (6.8M) | (6.8M) |
| Other Non-Op Income/Expense | (359.2M) | (278.3M) | 23.3M | (6.9M) | (6.9M) |
| Non-Operating Income (excl Interest) | 359.2M | 278.3M | (27.8M) | (1.4M) | (529.2K) |
| EBT (Pre-Tax Income) | (394.3M) | (293.4M) | 1.4M | (30.0M) | (32.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (394.3M) | (293.4M) | 1.4M | (30.0M) | (32.1M) |
| Earnings from Cont. Ops | (394.3M) | (293.4M) | 1.4M | (30.0M) | (32.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (422.7M) | (293.4M) | 1.4M | (30.0M) | (32.1M) |
| Per Share | |||||
| Basic EPS | ($28.37) | ($34.67) | $0.19 | ($4.61) | ($6.01) |
| Diluted EPS | ($28.87) | ($34.67) | $0.19 | ($4.61) | ($6.01) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 46.6M | 8.5M | 7.6M | 6.5M | 5.3M |
| Diluted Shares Outstanding | 79.1M | 8.5M | 7.6M | 6.5M | 5.3M |
| Profitability Metrics | |||||
| EBITDA | (394.3M) | (293.4M) | 6.0M | (21.7M) | (24.7M) |
| D&A | 2.7K | 5.4K | 22.5K | 31.0K | 8.5K |
| EBIT | (394.3M) | (293.4M) | 6.0M | (21.7M) | (24.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026